madrid, December 4, 2025 /PRNewswire/ — mAbxience, a Fresenius business, and HP Inc., a global technology leader, announced a new project to develop innovative artificial intelligence (AI) solutions to optimize monoclonal antibody and biosimilar production processes.
This project is a pioneering step in applying AI to industrial biotechnology through the creation of digital twins of biological processes designed to increase predictability, consistency, and efficiency in large-scale production. ”This is a clear example of purposeful technology. We use artificial intelligence to not only optimize processes, but also help get critical treatments to more people, faster and better.” said Sergio Martínez, technical lead for the project at HP.
Beyond technological innovation, this solution has transformative potential for all mAbxience partners, both biosimilar licensees and CDMO clients. By integrating AI into manufacturing operations, mAbxience aims to significantly optimize the development approach to biologics development, increase operational efficiency, and optimize resource utilization. This advancement strengthens the company’s position as a trusted and cost-competitive global biomanufacturing partner and helps optimize patient access to safe, high-quality biologics.
“Artificial intelligence may open many yet untapped possibilities for biomanufacturing optimization.” said Timo Liebig, Chief Innovation Officer at mAbxience.
“Through this collaboration with HP, we successfully developed our first prototype, enabling a more efficient, more robust, and more tightly controlled manufacturing campaign. This project demonstrates how technological innovation can directly lead to better access to essential biologic therapies for patients. ” Iván Sánchez, Director of Research and Development at mAbxience, said:
This development is based on real production data processed through advanced neural network models and validated in an industrial environment. The resulting tool will enable the mAbxience team to simulate, analyze, and optimize different stages of the cell culture manufacturing process, with the ultimate goal of increasing yield while reducing process variability.
The initiative will be the first project under HP and mAbxience’s strategic collaboration framework, which aims to apply AI to multiple key areas of the company to improve productivity, quality and sustainability across its global operations. The solution designed and validated at Leon has the potential to be replicated to other mAbxience sites and processes around the world.
Photo: https://mma.prnewswire.com/media/2838013/Mabxience.jpg
View original content to download multimedia: https://www.prnewswire.com/news-releases/mabxience-and-hp-drive-the-use-of-artificial-intelligence-in-biomanufacturing-and-biosimilar-development-302632307.html
Source mAbxience
